Skip to main content
SpringerLink
Log in

Novel Therapies for Pemphigus Vulgaris

An Overview

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Pemphigus comprises a group of autoimmune, mucocutaneous blistering disorders. Its principal cause may be a group of antibodies directed against proteins present on the surface of keratinocytes that provide mechanical structure to the epidermis. In the case of pemphigus vulgaris, the characteristic blistering noted just above the basal layer may be triggered by auto-antibodies directed against desmoglein 3 (Dsg3). The process by which the binding of these antibodies leads to acantholysis, apoptosis and eventual loss of epidermal function is not completely understood. Current therapies are primarily directed against the formation of these antibodies by suppression of the immune system, and are associated with significant adverse events. As our understanding of the pathophysiology of pemphigus increases, newer therapies have been proposed and evaluated. These novel therapies include intravenous immunoglobulin, plasmapheresis, immunoadsorption, extra-corporeal photochemotherapy, biological agents, as well as experimental therapies such as cholinergic receptor agonists, Dsg3 peptides and a p38 mitogen-activated protein kinase inhibitor. Current limitations to the widespread use of these therapies include cost, a lack of consistent data regarding their benefit, limited availability, and the experimental nature of some of the treatments. This review highlights the latest case reports and studies that employ established as well as new therapeutics in a novel way to treat this rare, but serious, disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Yeh SW, Ahmed B, Sami N, et al. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003; 16: 214–23

    Article  PubMed  CAS  Google Scholar 

  2. Baum S, Scope A, Barzilai A, et al. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 548–52

    Article  PubMed  CAS  Google Scholar 

  3. Eming R, Hertl M. Immunoadsorption in pemphigus. Auto-immunity 2006; 39: 609–16

    CAS  Google Scholar 

  4. Sonnenberg A, Liem RK. Plakins in development and disease. Exp Cell Res 2007; 313: 2189–203

    Article  PubMed  CAS  Google Scholar 

  5. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869–77

    Article  PubMed  CAS  Google Scholar 

  6. Nguyen VT, Ndoye A, Shultz LD, et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106: 1467–79

    Article  PubMed  CAS  Google Scholar 

  7. Kowalewski C, Hashimoto T, Amagai M, et al. IgA/IgG pemphigus: a new atypical subset of pemphigus? Acta Derm Venereol 2006; 86: 357–8

    Article  PubMed  Google Scholar 

  8. Huang Y, Li J, Zhu X. Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus. Arch Dermatol Res Epub 2008 Sep 27

    Google Scholar 

  9. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772–9

    Article  PubMed  CAS  Google Scholar 

  10. Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008; 144: 1621–4

    Article  PubMed  CAS  Google Scholar 

  11. Prajapati V, Mydlarski PR. Advances in pemphigus therapy. Skin Therapy Lett 2008; 13: 4–7

    PubMed  CAS  Google Scholar 

  12. Kwon EJ, Yamagami J, Nishikawa T, et al. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol 2008; 22: 1070–5

    Article  PubMed  CAS  Google Scholar 

  13. Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J Cutan Med Surg 2006; 10: 205–21

    PubMed  Google Scholar 

  14. Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970; 83: 315–23

    Article  PubMed  CAS  Google Scholar 

  15. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005; 366: 61–73

    Article  PubMed  Google Scholar 

  16. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol 1996; 132: 203–12

    Article  PubMed  CAS  Google Scholar 

  17. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984; 120: 941–51

    Article  PubMed  CAS  Google Scholar 

  18. Dick SE, Werth VP. Pemphigus: a treatment update. Autoimmunity 2006; 39: 591–9

    Article  PubMed  CAS  Google Scholar 

  19. Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962–70

    Article  PubMed  CAS  Google Scholar 

  20. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001; 33: 289–94

    Article  PubMed  CAS  Google Scholar 

  21. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138: 1158–62

    Article  PubMed  CAS  Google Scholar 

  22. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol 2005; 6: 327–42

    Article  PubMed  Google Scholar 

  23. Nousari CH, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 148–50

    Article  PubMed  Google Scholar 

  24. US National Institute of Health. Use of KC706 for the treatment of pemphigus vulgaris [online]. Available from URL: http://clinicaltrials.gov/ct2/results?term=NCT00606749 [Accessed 2009 Mar 11]

  25. Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008; 58: 796–801

    Article  PubMed  Google Scholar 

  26. Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006; 39: 601–7

    Article  PubMed  CAS  Google Scholar 

  27. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865–74

    Article  PubMed  CAS  Google Scholar 

  28. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679–90

    Article  PubMed  CAS  Google Scholar 

  29. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 358–63

    Article  PubMed  Google Scholar 

  30. Beckers RC, Brand A, Vermeer BJ, et al. Adjuvant highdose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289–93

    Article  PubMed  CAS  Google Scholar 

  31. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80: 41–7

    PubMed  Google Scholar 

  32. Ahmed AR. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin Investig Drugs 2004; 13: 1019–32

    Article  PubMed  CAS  Google Scholar 

  33. Sondergaard K, Carstens J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus: an update. Ther Apher 1997; 1: 155–8

    Article  PubMed  CAS  Google Scholar 

  34. Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124: 1659–63

    Article  PubMed  CAS  Google Scholar 

  35. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22: 35–40

    Article  PubMed  CAS  Google Scholar 

  36. Roujeau JC, Andre C, Joneau Fabre M, et al. Plasma exchange in pemphigus. uncontrolled study of ten patients. Arch Dermatol 1983; 119: 215–21

    Article  PubMed  CAS  Google Scholar 

  37. Blaszczyk M, Chorzelski TP, Jablonska S, et al. Indications for future studies on the treatment of pemphigus with plasmapheresis. Arch Dermatol 1989; 125: 843–4

    Article  PubMed  CAS  Google Scholar 

  38. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1058–64

    Article  PubMed  CAS  Google Scholar 

  39. Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148: 1222–9

    Article  PubMed  CAS  Google Scholar 

  40. Luftl M, Stauber A, Mainka A, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149: 598–605

    Article  PubMed  CAS  Google Scholar 

  41. Frost N, Messer G, Fierlbeck G, et al. Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of long-term history showing favorable outcome. Ann N Y Acad Sci 2005; 1051: 591–6

    Article  PubMed  Google Scholar 

  42. Shimanovich I, Herzog S, Schmidt E, et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006; 31: 768–74

    Article  PubMed  CAS  Google Scholar 

  43. Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212: 177–87

    Article  PubMed  Google Scholar 

  44. Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382–8

    Article  PubMed  CAS  Google Scholar 

  45. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992; 26: 779–80

    Article  PubMed  CAS  Google Scholar 

  46. Rook AH, Jegasothy BV, Heald P, et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 1990; 112: 303–5

    PubMed  CAS  Google Scholar 

  47. Gollnick HP, Owsianowski M, Taube KM, et al. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993; 28: 122–4

    Article  PubMed  CAS  Google Scholar 

  48. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology 1999; 198: 140–4

    Article  PubMed  CAS  Google Scholar 

  49. Schmidt E, Hunzelmann N, Zillikens D, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31: 503–8

    Article  PubMed  CAS  Google Scholar 

  50. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545–52

    Article  PubMed  CAS  Google Scholar 

  51. Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033–8

    Article  PubMed  CAS  Google Scholar 

  52. Marzano AV, Fanoni D, Venegoni L, et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology 2007; 214: 310–8

    Article  PubMed  CAS  Google Scholar 

  53. Feliciani C, Toto P, Amerio P, et al. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000; 114: 71–7

    Article  PubMed  CAS  Google Scholar 

  54. US National Institute of Health. Use of infliximab for the treatment of pemphigus vulgaris [online]. Available from URL: http://clinicaltrials.gov/ct2/results?term=NCT00283712[Accessed 2009 Mar 11]

  55. Iraji F, Yoosefi A. Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris. Int J Dermatol 2006; 45: 743–6

    Article  PubMed  CAS  Google Scholar 

  56. Nguyen VT, Arredondo J, Chernyavsky AI, et al. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004; 140: 327–34

    Article  PubMed  CAS  Google Scholar 

  57. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80–6

    Article  PubMed  CAS  Google Scholar 

  58. Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol 2005; 125: 1093–8

    Article  PubMed  CAS  Google Scholar 

  59. Berger M, Rosenkranz P, Brown CY. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 1985; 34: 227–36

    Article  PubMed  CAS  Google Scholar 

  60. Shimozato T, Iwata M, Kawada H, et al. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology 1991; 72: 497–501

    PubMed  CAS  Google Scholar 

  61. Segura S, Iranzo P, Martinez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007; 56: 960–7

    Article  PubMed  Google Scholar 

  62. Perez M, Edelson R, Laroche L, et al. Inhibition of antiskin allograft immunity by infusions with syngeneic photo-inactivated effector lymphocytes. J Invest Dermatol 1989; 92: 669–76

    Article  PubMed  CAS  Google Scholar 

  63. Laroche L, Edelson RL, Perez M, et al. Antigen-specific tolerance induced by autoimmunization with photoinactivated syngeneic effector cells. Ann NY Acad Sci 1991; 636: 113–23

    Article  PubMed  CAS  Google Scholar 

  64. Pfutze M, Eming R, Kneisel A, et al. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009; 218: 237–45

    Article  PubMed  Google Scholar 

  65. Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, et al. TNFα and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001; 40: 185–8

    Article  PubMed  CAS  Google Scholar 

  66. Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005; 153: 222–3

    Article  PubMed  CAS  Google Scholar 

  67. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005; 153: 448–9

    Article  PubMed  CAS  Google Scholar 

  68. Mehta JN, Martin AG. A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol 2000; 136: 15–17

    Article  PubMed  CAS  Google Scholar 

  69. Berkowitz P, Hu P, Liu Z, et al. Desmosome signaling: inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J Biol Chem 2005; 280: 23778–84

    Article  PubMed  CAS  Google Scholar 

  70. Berkowitz P, Hu P, Warren S, et al. p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci U S A 2006; 103: 12855–60

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Pittsburgh Medical Center, Shady Side Place, 580 South Aiken Avenue, Suite 200, Pittsburgh, Pennsylvania, 15232, USA

    Oliver A. Perez &  Timothy Patton

Authors
  1. Oliver A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Patton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy Patton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez, O.A., Patton, T. Novel Therapies for Pemphigus Vulgaris. Drugs Aging 26, 833–846 (2009). https://doi.org/10.2165/11316810-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11316810-000000000-00000

Keywords

Search

Navigation